Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Operating Margin (2017 - 2025)

Historic Operating Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 6450.83%.

  • Vistagen Therapeutics' Operating Margin rose 107100.0% to 6450.83% in Q4 2025 from the same period last year, while for Dec 2025 it was 8847.85%, marking a year-over-year decrease of 9024300.0%. This contributed to the annual value of 11517.08% for FY2025, which is 84136000.0% down from last year.
  • Vistagen Therapeutics' Operating Margin amounted to 6450.83% in Q4 2025, which was up 107100.0% from 7772.48% recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Operating Margin peaked at 96633.33% during Q1 2025, and registered a low of 42802.56% during Q1 2022.
  • Moreover, its 5-year median value for Operating Margin was 5901.1% (2022), whereas its average is 2049.0%.
  • As far as peak fluctuations go, Vistagen Therapeutics' Operating Margin plummeted by -413955500bps in 2022, and later skyrocketed by 1035595500bps in 2025.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Operating Margin stood at 2943.85% in 2021, then plummeted by -84bps to 5425.83% in 2022, then skyrocketed by 65bps to 1918.25% in 2023, then tumbled by -237bps to 6461.54% in 2024, then increased by 0bps to 6450.83% in 2025.
  • Its Operating Margin stands at 6450.83% for Q4 2025, versus 7772.48% for Q3 2025 and 6477.05% for Q2 2025.